Curapath is a leading CDMO specializing in innovative drug delivery systems (DDS), with expertise in lipid nanoparticles (LNPs) and polymer nanoparticles (PNPs). Offering comprehensive support from development to IND filing, Curapath provides GMP manufacturing of Drug Substance and Drug Product for clinical trials. The company excels in custom design, development, and GMP manufacturing of lipid- and polymer-based delivery systems critical to cell therapies, gene therapies, and vaccines. With over a decade of experience, Curapath has supported drug innovators in creating stealth shielding polymers, functional excipients, bioconjugation linkers, and API polymers for therapeutics. A proven track record and consultative guidance ensure seamless progression from preclinical development to commercial-scale manufacturing. Curapath addresses complex drug delivery challenges, accelerating speed to clinic and providing reliable expertise to bring innovative therapies to patients efficiently.